Singapore Airlines sued for allegedly serving Shrimp to a business-class US passenger: Report
Also Read - 'Don't do this': Y Combinator CEO Garry Tan slams LinkedIn user flexing AI mega event as work experience
In a lawsuit filed in the United States, Dr Doreen Benary said she had clearly communicated her shrimp allergy to one or more crew members upon boarding her business class seat on a flight from Frankfurt to New York (JFK) on October 8, 2024. However, court documents, accessed by the publication alleged that the crew still served her a meal that contained shrimp, a mistake that nearly turned fatal. Doctor undergoes treatment in Paris
Unaware of the contents, Dr Benary consumed a portion of the meal. She reportedly realised something was wrong only after she began to feel unwell and detected the presence of shrimp. According to the lawsuit, when she raised the alarm, a flight attendant allegedly admitted the error and offered an apology. But by then, the damage was done.
The report further said that the allergic reaction was so severe that the aircraft had to make an emergency diversion to Paris, where Dr Benary was rushed to hospital by ambulance. She underwent urgent treatment at two separate medical facilities, the documents state.
Also Read - Japan PM's wife leads International Yoga Day celebrations in Tokyo with over 2,000 participants
Describing the ordeal, Dr Benary said she endured 'great pain, agony, and mental anguish', and was forced to go through 'painful, emergency medical procedures,' all because of what she alleges was gross negligence by the airline crew.
The lawsuit, which brings renewed attention to how airlines handle passengers with severe food allergies, comes at a time when global carriers are under increasing scrutiny for in-flight safety protocols, especially concerning dietary restrictions and medical preparedness.
Singapore Airlines has yet to publicly comment on the matter.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Mint
27 minutes ago
- Mint
Inside Cipla's battle with ‘superbugs' as antibiotic resistance rises in India
Mumbai-headquartered drugmaker Cipla Ltd is bolstering its focus on a pipeline of drugs to fight infections caused by bacterial antimicrobial resistance in India, a growing health crisis. The company, a leader in the infectious diseases segment, has already launched two antibiotics targetting such superbugs, and sees the segment as a long-term focus area, a senior executive told Mint. 'Since we began our work on (antimicrobial drug resistance), our strategic plan has been to introduce three to four products in the AMR space over a 5-year horizon," Dr. Jaideep Gogtay, Cipla's global chief medical officer, said in an interview. 'I think it will be a long-term strategy. As a company which remains focused on India, there is no option for us to not be in the antibiotics segment," Gogtay added. Antimicrobial drug resistance occurs when microorganisms like bacteria or fungi evolve to resist the drugs designed to kill or inhibit them. These 'superbugs' render existing treatments ineffective and can lead to escalation of the infection, and cause death as well. Bacterial antimicrobial resistance was associated with 4.71 million global deaths in 2021, according to a Lancet study. This could increase to 39 million by 2050. India, which is one of the world's largest antibiotic markets, also has one of the highest burdens of drug resistance. Overuse of antibiotics is leading to increasing resistance in the community, while new drug development has not kept pace with the growing threat. 'Out of every 100 new drugs developed, only one or two are antibiotics. Although we know, in the future antibiotic-resistant infections are going to probably kill more people than cancer infections," Gogtay said. Globally, the development focus has shifted away from infectives and antibiotics to therapies like cancer and obesity, with most large pharma companies exiting antibiotic research. Cipla's pipeline Cipla has launched two drugs targeted at bacterial AMR in the past year. In May, it became the first company to launch plazomicin, marketed under brand name Zemdri, in India, a novel anti-microbial with demonstrated activity against multi-drug resistant bacteria and clinical efficacy in complicated urinary tract infections (cUTI). Clinical efficacy refers to how well a drug or treatment method achieves its intended effect under controlled clinical trials. Last year, Cipla partnered with Chennai-based Orchid Pharma Ltd to launch its novel antibiotic Cefepime-Enmetazobactam, which has been approved for the treatment of cUTIs, hospital-acquired pneumonia, and ventilator-associated pneumonia. The company plans to launch this year a non-antibiotic that can be used to prevent cUTIs without the risk of developing resistance. 'We are working with a partner, and the product has been approved in India. We will launch this product in India shortly," said Gogtay. For 2024-25, Cipla reported a revenue of ₹27,548 crore, up 8% year-on-year, while profit after tax surged 28% to ₹5,273 crore. How big is the market? The overall market for anti-infective drugs in India was ₹26,824 crore in May in terms of moving annual total (MAT) sales, according to pharma intelligence platform Pharmarack. Of this, antibiotics accounted for sales worth ₹23,127 crore. (MAT sales refers to total sales over the past 12 months, calculated on a rolling basis.) However, it is hard to zero in on the size of the market for drugs specifically targeted at drug-resistant bacteria, according to experts. Drugs that target antimicrobial drug resistance are given after the first or second line of antibiotics prove to be ineffective in treating a patient. However, as resistance increases, the market is growing. 'Here, what they (Cipla) seem to be trying to do is identify certain areas which may be meaningful over a period of time and try to get in early. They are trying to be early in an area that may become a lot more relevant in the future," said Prashant Nair, analyst for healthcare and pharma at Ambit Capital. Anti-infective medicines make for a key therapy segment for Cipla, after respiratory, cardiac and urology, said Nair. 'Most players who are strong in anti-infectives therapy may be looking at this space." Apart from Cipla, Wockhardt Ltd too has been sharpening its focus on antimicrobial drug resistance, with a pipeline of six novel antibiotics, of which two have been launched in India. As on 3 July, Cipla shares were down by about 1.4% each since the beginning of the year, while Wockhardt shares were up nearly 20% on NSE. The Nifty Pharma index was down more than 5% year-to-date.
Time of India
3 hours ago
- Time of India
The Fittest Doc reveals 5 daily habits to save your heart: No cost, just results
Think protecting your heart means strict diets and hours at the gym? Think again. According to Dr Nicholas Nwabueze, a US-based physician better known as The Fittest Doc, heart health doesn't need to be complicated. In fact, just five minutes a day can make a big difference, if you know what to focus on. Here are five small daily habits he swears by, and they're backed by science too. 1. Take a Short Walk After Every Meal Instead of sinking into the sofa after lunch or dinner, walk for 5–10 minutes. That simple step can help control blood sugar levels and reduce inflammation, two things that directly impact heart health. Even a 2-minute stroll after a meal helps your muscles absorb glucose from the bloodstream, keeping energy levels stable and your heart protected. It's not about burning calories, it's about keeping your system steady. 2. Catch the Morning Sunlight No, this isn't just about getting your daily dose of vitamin D. Morning sunlight helps regulate your body clock, which in turn improves your sleep quality, something deeply linked to heart health. Live Events Exposing your skin to sunlight in the first hour of waking resets your circadian rhythm, reduces stress hormones, and lowers the risk of high blood pressure and heart attacks. Think of it as a natural reset button for your heart every morning. 3. Ditch Plastic Food Containers Still heating your food in plastic containers? Dr Nwabueze says stop now. Many plastics release harmful chemicals like BPA and phthalates when heated, which mess with hormones and raise your heart disease risk. Swap plastic for glass or stainless steel, especially when storing or microwaving food. It's a small switch that protects your heart and your hormones. 4. Forget Motivation, Focus on Micro-Habits Waiting to feel motivated to start that health routine? Don't. According to Dr Nwabueze, it's the tiny actions we take daily, not big resolutions, that build real heart health. Try standing while taking phone calls, prepping meals once a week, or choosing the stairs over the lift. Small, steady habits add up, and over time, they become heart-saving rituals. 5. Move More, Sit Less Yes, even if you exercise regularly, sitting too long can still harm your heart. Studies show that people who sit more than 10 hours a day have a 34% higher risk of heart disease, even if they hit the gym later. The solution? Stand up and move every 30 minutes. Just 2–3 minutes of walking, stretching, or pacing is enough to improve circulation and lower your heart risk.
News18
3 hours ago
- News18
COVID-19 Vaccines and Heart Attacks: What You Really Need to Know
Last Updated: COVID-19 vaccines are overwhelmingly safe, with far lower heart risks than the infection itself. Recent reports of sudden cardiac deaths, particularly in Karnataka's Hassan district where 23 people died of heart attacks within 40 days, have stirred public concern over a possible link between COVID-19 vaccines and heart complications. However, health experts and investigations by ICMR and AIIMS have found no evidence directly connecting these heart attacks to the COVID-19 vaccine. According to Dr. Basavaraj Utagi, Senior Consultant Cardiologist, Fortis Hospital, 'COVID-19 infection itself carries a far greater risk of heart-related issues than the vaccine. Inflammation of the heart muscle, or myocarditis, is much more likely after infection than after vaccination." While global health agencies, including the U.S. FDA, have acknowledged rare cases of myocarditis particularly in young men following mRNA vaccines like Pfizer and Moderna, these incidents remain extremely uncommon. Most cases are mild and resolve with minimal treatment. As a precaution, the FDA has mandated updated labeling to reflect these risks, promoting transparency rather than alarm. Dr. Jeffrey Carstens, Cardiovascular Medical Director, UnityPoint Health, echoes this perspective: 'Yes, myocarditis after vaccination can happen, but it's very rare and generally not severe. On the other hand, COVID-19 infection can trigger dangerous inflammation that leads to heart attacks, arrhythmias, or heart failure." In fact, several studies show that COVID-19 vaccines may actually reduce the risk of heart attacks and strokes. A UK-based study found that vaccinated individuals had a lower incidence of arterial blockages, while Mount Sinai researchers observed fewer major cardiac events among vaccinated COVID patients. COVID-19 vaccines are overwhelmingly safe and remain a critical shield especially for older adults and those with existing health issues. The risk of severe heart problems is far greater from COVID infection than from the vaccine itself. If you experience symptoms like chest pain or shortness of breath post-vaccination, seek medical advice—but know that such cases are rare. In the debate between fear and fact, science continues to back the vaccine.
